Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RadnostixINIS Equity-to-Asset is 0.11 as of Jun. 2026, which is 27% below its 10-year median of 0.15. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Radnostix ranks worse than 90.38% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Radnostix's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $1.89 Mil. Radnostix's Total Assets for the quarter that ended in Jun. 2026 was $16.65 Mil.
Therefore, Radnostix's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.11.
The historical rank and industry rank for Radnostix's Equity-to-Asset or its related term are showing as below:
INIS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.17 Med: 0.15 Max: 0.3
Current: 0.11
During the past 13 years, the highest Equity to Asset Ratio of Radnostix was 0.30. The lowest was -0.17. And the median was 0.15.
INIS's Equity-to-Asset is ranked worse than 90.38% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs INIS: 0.11
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Radnostix Equity-to-Asset Related Terms
Radnostix Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Radnostix's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INIS vs RMTI, MRMD, RAPH: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Radnostix's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Radnostix's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radnostix (INIS) has a Equity-to-Asset of 0.11 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Radnostix and its competitors. This is 27% below median its historical median of 0.15. According to the industry distribution chart, Radnostix ranks #911 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 90.4%.
Is Radnostix's Equity-to-Asset too high?
Radnostix's current Equity-to-Asset of 0.11 is 27% below median its 10-year median of 0.15. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Radnostix's value of 0.11 is 81.7% below this industry median. Based on the distribution chart, Radnostix ranks #911 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Radnostix's Equity-to-Asset compare to RMTI and MRMD?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #911 out of 1008 companies for Equity-to-Asset. This places Radnostix in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Radnostix's value of 0.11 is 81.7% below this benchmark. While the company's 10-year median is 0.15 vs. the industry median of 0.60, Radnostix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radnostix's current Equity-to-Asset of 0.11 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current Equity-to-Asset is 0.11, which is 27% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.06 — trading 37.5% above its estimated fair value. The current Equity-to-Asset is 0.11, which is 27% below median its 10-year median of 0.15 and 81.7% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Radnostix (INIS), the current Equity-to-Asset is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 
